Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(14%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
57%
Ph early_phase_1
3
43%

Phase Distribution

7

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
3(42.9%)
Phase 1Safety & dosage
4(57.1%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Completed(1)
Other(1)

Detailed Status

Not yet recruiting3
Completed1
unknown1
Recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 13 (42.9%)
Phase 14 (57.1%)

Trials by Status

completed114%
not_yet_recruiting343%
unknown114%
recruiting114%
enrolling_by_invitation114%

Recent Activity

1 active trials
Showing 5 of 7
not_yet_recruitingearly_phase_1

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

NCT07519187
not_yet_recruitingearly_phase_1

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

NCT06986434
not_yet_recruitingearly_phase_1

CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

NCT07416682
enrolling_by_invitationphase_1

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

NCT07168486
recruitingphase_1

Chidamide Bridging for CAR-T Therapy

NCT05370547
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07519187Early Phase 1

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Not Yet Recruiting
NCT06986434Early Phase 1

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

Not Yet Recruiting
NCT07416682Early Phase 1

CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

Not Yet Recruiting
NCT07168486Phase 1

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

Enrolling By Invitation
NCT05370547Phase 1

Chidamide Bridging for CAR-T Therapy

Recruiting
NCT03173417Phase 1

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Completed
NCT03208556Phase 1

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7